BRCA2 and colorectal carcinoma: While there is no consensus on the impact of germline BRCA2 mutations on CRC risk, a series of studies have shown that, in patients with CRC, BRCA mutations might increase the likelihood of response to oxaliplatin-based chemotherapy [3].